US 12,215,321 B2
Modulators of diacyglycerol acyltransferase 2 (DGAT2)
Eric E. Swayze, Encinitas, CA (US)
Assigned to Ionis Pharmaceuticals, Inc., Carlsbad, CA (US)
Filed by Ionis Pharmaceuticals, Inc., Carlsbad, CA (US)
Filed on Feb. 22, 2022, as Appl. No. 17/677,875.
Application 17/677,875 is a continuation of application No. 16/456,432, filed on Jun. 28, 2019, granted, now 11,312,962.
Application 16/456,432 is a continuation of application No. 15/741,996, abandoned, previously published as PCT/US2016/041410, filed on Jul. 8, 2016.
Claims priority of provisional application 62/191,231, filed on Jul. 10, 2015.
Prior Publication US 2023/0047452 A1, Feb. 16, 2023
Int. Cl. C12N 15/113 (2010.01); A61P 1/16 (2006.01); C07H 21/00 (2006.01)
CPC C12N 15/1137 (2013.01) [A61P 1/16 (2018.01); C07H 21/00 (2013.01); C12Y 203/0102 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/341 (2013.01); C12N 2310/346 (2013.01); C12N 2320/35 (2013.01)] 13 Claims
 
1. A method of treating, preventing, or ameliorating NAFLD, NASH, lipodystrophy, or partial lipodystrophy in an individual comprising administering to the individual a compound comprising or consisting of a modified oligonucleotide according to the following formula:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a salt thereof;
wherein administering the compound reduces or inhibits triglyceride synthesis, lipid synthesis and/or insulin resistance in the liver or white adipose tissue of the individual;
thereby treating, preventing, or ameliorating NAFLD, NASH, lipodystrophy, or partial lipodystrophy.